Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjects M. SibilleV. BressonD. Vital Durand CLINICAL TRIALS Pages: 81 - 86
A comparison of two cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a large phase IV study E. WagerP. J. H. TooleyR. D. Mann CLINICAL TRIALS Pages: 87 - 94
Carvedilol versus verapamil in chronic stable angina: a multicentre trial U. Hauf-ZachariouR. A. BlackwoodE. Pfarr CLINICAL TRIALS Pages: 95 - 100
Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia K. RašlováD. DubovskáT. Trnovec PHARMACODYNAMICS Pages: 101 - 106
Comparison of the antinociception produced by two oral formulations of ibuprofen: ibuprofen effervescent vs ibuprofen tablets T. HummelO. CramerG. Kobal PHARMACODYNAMICS Pages: 107 - 114
Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man G. FleschP. MüllerP. Lloyd PHARMACOKINETICS AND DISPOSITION Pages: 115 - 120
MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography M. BergströmG. WesterbergB. Långström PHARMACOKINETICS AND DISPOSITION Pages: 121 - 128
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms O. SpigsetK. GranbergR. Dahlqvist PHARMACOKINETICS AND DISPOSITION Pages: 129 - 133
Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients P. A. Le CorreE. R. PeskindR. Le Verge PHARMACOKINETICS AND DISPOSITION Pages: 135 - 138
Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men J. LundahlC. G. RegårdhG. Johnsson PHARMACOKINETICS AND DISPOSITION Pages: 139 - 145
Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes P. Rady-PentekR. MuellerW. Kalow PHARMACOKINETICS AND DISPOSITION Pages: 147 - 153
In reply to the letter to the editor by Jackson and Yeo entitled Cross-over trials-a commentary T. J. M. Cleophas REPLY Pages: 157 - 158
Comment on “Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine” K. Yeleswaram LETTERS TO THE EDITOR Pages: 159 - 159
Comment on “Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine” J. K. MadsenJ. D. JensenE. B. Pedersen LETTERS TO THE EDITOR Pages: 161 - 161